naropin 7.5mgml-20ml polyamp (blister pack) solution for injection
aspen medical products malaysia sdn bhd - ropivacaine hcl -
naropin 2mgml-20ml polyamp
aspen medical products malaysia sdn bhd - ropivacaine hcl -
nimbex injection 2mg/ml
aspen medical products malaysia sdn bhd - cisatracurium besylate -
aggrastat 0.25mgml concentrate for infusion
aspen medical products malaysia sdn bhd - tirofiban hydrochloride monohydrate -
marcain spinal 0.5% heavy 4ml
aspen medical products malaysia sdn bhd - bupivacaine hydrochloride monohydrate. -
ultiva injection 5mg
aspen medical products malaysia sdn bhd - remifentanil hydrochloride -
xylocaine 2% inj (5ml polyamp)
aspen medical products malaysia sdn bhd - lignocaine hcl/lidocaine hcl -
marcaine 0.5% with adrenaline injection
aspen medical products malaysia sdn bhd - bupivacaine hydrochloride; adrenaline acid tartrate -
sustanon 250 injection (1ml amp)
aspen medical products malaysia sdn bhd - testosterone propionate; testosterone phenylpropionate; testosterone decanoate; testosterone isocaproate -
aspen ciprofloxacin ciprofloxacin injection for intravenous infusion 200mg/100ml bag
aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.